Skip to main content
. Author manuscript; available in PMC: 2017 Jan 6.
Published in final edited form as: Biomed Pharmacother. 2016 Nov 26;85:399–411. doi: 10.1016/j.biopha.2016.11.043

Fig. 2.

Fig. 2

BMP pathway inhibition acts with FGF2 in maintenance of stemness in vitro. (A) Histological examination of paraffined PTC samples (magnitude 40×, 63×, 40×, respectively; optical microscope). (B) CSC-enriched cell cultures isolated from the same PTC samples, able to maintain the double (adherent and floating) population in culture (magnitude 20×; optical microscope). (C) FACS analysis on CSC-enriched cell cultures for SOX2, OCT3, PAX8, TTF1, ERA, and ERB after treatment with FGF2 and NOGGIN. Conditions: control; 1 ug/100 mL FGF2; 10 ug/100 mL NOGGIN + 1 ug/100 mL FGF2; 10 ug/100 mL NOGGIN + 4 ug/100 mL FGF2. 48 h treatment.